CLINICAL TRIALS PROFILE FOR CEFTAZIDIME SODIUM

All Clinical Trials for Ceftazidime Sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00333385 ↗	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis	Terminated	Baxter Healthcare Corporation	Phase 4	2001-10-01	The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis	Terminated	GlaxoSmithKline	Phase 4	2001-10-01	The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis	Terminated	Roche Pharma AG	Phase 4	2001-10-01	The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis	Terminated	Vaincre la Mucoviscidose	Phase 4	2001-10-01	The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.

Clinical Trial Conditions for Ceftazidime Sodium

Condition Name

Condition Name for Ceftazidime Sodium
Intervention	Trials
Pulmonary Exacerbation	1
Respiratory Tract Infections	1
Urinary Tract Infections	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for Ceftazidime Sodium
Intervention	Trials
Fibrosis	1
Urinary Tract Infections	1
Cystic Fibrosis	1
Respiratory Tract Infections	1

Clinical Trial Locations for Ceftazidime Sodium

Trials by Country

Trials by Country for Ceftazidime Sodium
Location	Trials
China	2
France	1
Brazil	1

Clinical Trial Progress for Ceftazidime Sodium

Clinical Trial Phase

Clinical Trial Phase for Ceftazidime Sodium
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	2
N/A	1

Clinical Trial Status

Clinical Trial Status for Ceftazidime Sodium
Clinical Trial Phase	Trials
Completed	1
Terminated	1
Enrolling by invitation	1

Clinical Trial Sponsors for Ceftazidime Sodium

Sponsor Name

Sponsor Name for Ceftazidime Sodium
Sponsor	Trials
Arrevus Inc.	1
Baxter Healthcare Corporation	1
GlaxoSmithKline	1

Sponsor Type

Sponsor Type for Ceftazidime Sodium
Sponsor	Trials
Industry	5
Other	5